Rem3dy Health raises £14M Series A to scale 3D-printed personalised vitamins globally
What's the deal? UK-based Rem3dy Health, the parent company of personalised vitamin brand Nourished, has raised £14M at an £84M valuation. The round was led by strategic investors including SuntoryDealroom has a profile for this one. Try Dealroom →, Estrella GaliciaDealroom has a profile for this one. Try Dealroom →, Apollo HospitalsDealroom has a profile for this one. Try Dealroom →, and UPSADealroom has a profile for this one. Try Dealroom →, with participation from Future Planet Capital RegionalDealroom has a profile for this one. Try Dealroom →.
Rem3dy uses patented 3D printing technology to produce personalised vitamin gummies — roughly 500,000 per day. The company holds 29 patents and has retail presence across BootsDealroom has a profile for this one. Try Dealroom →, Holland & Barrett, and Ocado. The fresh capital will fund expansion into the US, the MENA region, and India, alongside continued AI and manufacturing investment.
Why now? The raise follows a strong 2025 for the company. Revenue grew 61% to £10.2M, and production yield improved to 97%. The round also follows a smaller £1.4M raise in late 2025 led by Borski FundDealroom has a profile for this one. Try Dealroom →, suggesting mounting investor appetite.
"Following a year of significant transformation and against one of the toughest fundraising environments in recent years, we are now in a strong position to scale globally," said founder Melissa Snover.
What could go wrong? International expansion is expensive and complex, especially into markets as diverse as the US, India, and the Middle East. Personalised nutrition remains a crowded space, and Rem3dy will need to prove its 3D printing edge translates across regulatory regimes and consumer cultures. Scaling manufacturing while maintaining 97% yield is no small feat either.
The signal: Every investor in this round is a corporate backer — Suntory, Estrella Galicia, Apollo Hospitals, and UPSA all sit in the corporate investor category according to Dealroom — meaning Rem3dy has effectively assembled a syndicate of potential distribution partners rather than traditional financial backers. That structure hints at a commercialisation-first strategy: each corporate brings a ready-made channel (beverages, healthcare, consumer pharmacy) that could accelerate Rem3dy's path into new geographies far faster than venture capital alone.
Read more: femtechinsider.com
